1169 related articles for article (PubMed ID: 10327070)
1. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab and chemotherapeutics: drug interactions and synergies.
Pegram MD; Lopez A; Konecny G; Slamon DJ
Semin Oncol; 2000 Dec; 27(6 Suppl 11):21-5; discussion 92-100. PubMed ID: 11236023
[TBL] [Abstract][Full Text] [Related]
3. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
Baselga J; Norton L; Albanell J; Kim YM; Mendelsohn J
Cancer Res; 1998 Jul; 58(13):2825-31. PubMed ID: 9661897
[TBL] [Abstract][Full Text] [Related]
4. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
Pietras RJ; Poen JC; Gallardo D; Wongvipat PN; Lee HJ; Slamon DJ
Cancer Res; 1999 Mar; 59(6):1347-55. PubMed ID: 10096569
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
Gong SJ; Jin CJ; Rha SY; Chung HC
Cancer Lett; 2004 Oct; 214(2):215-24. PubMed ID: 15363548
[TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
9. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
10. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Pegram MD; Konecny GE; O'Callaghan C; Beryt M; Pietras R; Slamon DJ
J Natl Cancer Inst; 2004 May; 96(10):739-49. PubMed ID: 15150302
[TBL] [Abstract][Full Text] [Related]
11. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
[TBL] [Abstract][Full Text] [Related]
12. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
Holmes FA
Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification.
Tomioka H; Mukohara T; Kataoka Y; Ekyalongo RC; Funakoshi Y; Imai Y; Kiyota N; Fujiwara Y; Minami H
Int J Oncol; 2012 Aug; 41(2):551-8. PubMed ID: 22614071
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
17. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
20. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
